Cargando…

Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial

BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) reduce the risk of atrial fibrillation (AF) in patients with heart failure (HF) and a reduced ejection fraction. The efficacy of MRAs for AF prevention in patients with HF and a preserved ejection fraction (HFpEF) is unclear. OBJECTIVES: We p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neefs, Jolien, van den Berg, Nicoline W. E., Krul, Sébastien P. J., Boekholdt, S. Matthijs, de Groot, Joris R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978290/ https://www.ncbi.nlm.nih.gov/pubmed/31214914 http://dx.doi.org/10.1007/s40256-019-00353-5

Ejemplares similares

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022)

Sex Differences in Characteristics and Outcomes in Elderly Heart Failure Patients With Preserved Ejection Fraction: A Post-hoc Analysis From TOPCAT
por: Sun, Jiaxing, et al.
Publicado: (2021)

Weight cycling and risk of clinical adverse events in patients with heart failure with preserved ejection fraction: a post-hoc analysis of TOPCAT
por: Tan, Yi, et al.
Publicado: (2023)

Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT
por: Dong, Bin, et al.
Publicado: (2020)

Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial
por: De Marco, Corrado, et al.
Publicado: (2021)

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
por: ElGuindy, Ahmed M.
Publicado: (2013)

Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas
por: Bajaj, Navkaranbir S., et al.
Publicado: (2020)

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
por: Choy, Manting, et al.
Publicado: (2022)

Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score–Matched Analysis of the TOPCAT Americas Trial
por: Saksena, Sanjeev, et al.
Publicado: (2023)

Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
por: Wei, Fang‐Fei, et al.
Publicado: (2020)

Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial
por: Wu, Yuzhong, et al.
Publicado: (2020)

Impact of Sex on Ventricular‐Vascular Stiffness and Long‐Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy
por: Beale, Anna L., et al.
Publicado: (2019)

Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
por: Peters, Anthony E., et al.
Publicado: (2021)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
por: Shantsila, Eduard, et al.
Publicado: (2020)

C(2)HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial
por: Liang, Weihao, et al.
Publicado: (2021)

Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial
por: Kim, Morris M., et al.
Publicado: (2023)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020)

A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction
por: Belkin, Mark N., et al.
Publicado: (2021)

Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
por: Pandey, Ambarish, et al.
Publicado: (2018)

Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial
por: Liang, Weihao, et al.
Publicado: (2021)

MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications
por: van den Berg, Nicoline W. E., et al.
Publicado: (2017)

Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Li, Shuai, et al.
Publicado: (2018)

Outcomes of Spironolactone Withdrawal in Dilated Cardiomyopathy With Improved Ejection Fraction
por: Chen, Yanjia, et al.
Publicado: (2021)

Clinical course of sinus node dysfunction after thoracoscopic surgery for atrial fibrillation—analysis of the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (AFACT) study
por: Neefs, Jolien, et al.
Publicado: (2020)

IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial
por: Shantsila, Eduard, et al.
Publicado: (2016)

Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials
por: Xiang, Yajie, et al.
Publicado: (2019)

Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial
por: Dong, Bin, et al.
Publicado: (2022)

Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial
por: Silverman, Daniel N., et al.
Publicado: (2019)

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis
por: van den Berg, Maarten P, et al.
Publicado: (2019)

Thoracoscopic surgical atrial fibrillation ablation in patients with an extremely enlarged left atrium
por: Neefs, Jolien, et al.
Publicado: (2021)

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
por: Enzan, Nobuyuki, et al.
Publicado: (2020)

Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2022)

Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation
por: Ţica, Otilia, et al.
Publicado: (2022)

Poorer Exercise Accommodation of Regional Systolic Myocardial Motion after Spironolactone Treatment in Heart Failure Patients with Preserved Ejection Fraction and Ventricular Dyssynchrony
por: Yu, Chih-Chieh, et al.
Publicado: (2021)

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
por: Schnelle, Moritz, et al.
Publicado: (2021)

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial
por: Squire, Iain B., et al.
Publicado: (2022)

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk
por: Li, Jun-Feng, et al.
Publicado: (2023)

Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials
por: Kresoja, Karl-Patrik, et al.
Publicado: (2023)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation
por: Ahn, Min-Soo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5091hsht90tah3vb65qi8h4jht